These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33684852)

  • 1. Simple mathematical data processing method for the determination of sever overlapped spectra of linagliptin and empagliflozin in their pure forms and pharmaceutical formulation: Fourier self deconvulated method.
    Elmasry MS; Hassan WS; Merey HA; Nour IM
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Jun; 254():119609. PubMed ID: 33684852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma.
    Elmasry MS; Hasan MA; Hassan WS; Merey HA; Nour IM
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Mar; 248():119258. PubMed ID: 33310272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative UV Protocols Based on Straightforward Mathematical Filtration for Concurrent Estimation of Two Antidiabetic Drugs in Their Brand-New Combination: A Comparative Study.
    Nour IM; Mohamed AR; Badrawy M
    J AOAC Int; 2024 Jan; 107(1):40-45. PubMed ID: 37824214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid LC-PDA method for the simultaneous quantification of metformin, empagliflozin and linagliptin in pharmaceutical dosage form.
    Gollu G; Gummadi S
    Ann Pharm Fr; 2022 Jan; 80(1):48-58. PubMed ID: 34157314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous estimation of two anti-diabetic drugs; Linagliptin and empagliflozin in their tablet by chemometric spectrophotometry.
    Kamal AH; Hammad SF; Salim MM; Elkhodary MM; Marie AA
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jan; 305():123556. PubMed ID: 37866257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form.
    Moussa BA; Mahrouse MA; Fawzy MG
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Dec; 205():235-242. PubMed ID: 30025293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of simple spectrophotometric and chemometric methods for simultaneous determination of empagliflozin and metformin: Applied to recently approved pharmaceutical formulation.
    Ayoub BM
    Spectrochim Acta A Mol Biomol Spectrosc; 2016 Nov; 168():118-122. PubMed ID: 27288963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin.
    Gurrala S; Raj S; Cvs S; Anumolu PD
    J Chromatogr Sci; 2022 Jan; 60(1):68-80. PubMed ID: 33822920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.
    M Amin KF; Abdullah AM; Fakhre NA
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Nov; 222():117261. PubMed ID: 31228859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of linagliptin and empagliflozin by UPLC and HPTLC techniques aided by lean six sigma approach.
    El-Desouky EA; Abdel-Raoof AM; Abdel-Fattah A; Abdel-Zaher A; Osman AOE; Abdel-Monem AH; Morshedy S
    Biomed Chromatogr; 2021 Jul; 35(7):e5102. PubMed ID: 33629452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous spectrophotometric determination of compounds having relatively disparate absorbance and concentration ranges; application to antidiabetic formulation of linagliptin and metformin.
    Abdalla OM; Abdel-Megied AM; Saad AS; Soliman SS
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Oct; 203():112-117. PubMed ID: 29860167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases.
    Hammad RW; Sanad RA; Abdelmalak NS; Latif R
    Int J Biol Macromol; 2022 Nov; 220():1429-1443. PubMed ID: 36115452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: Recent advances in synergistic strategies for maximizing control of high-risk type II diabetes.
    Hammad RW; Sanad RA; Abdelmalak NS; Latif R
    Drug Deliv Transl Res; 2024 Mar; 14(3):678-695. PubMed ID: 37805954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
    Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A
    Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel univariate spectrophotometric determination of the recently released solid dosage form comprising dapagliflozin and saxagliptin via factorized response spectra: Assessment of the average content and dosage unit uniformity of tablets.
    Lotfy HM; Mohamed D; Elshahed MS
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Nov; 222():117120. PubMed ID: 31252262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.